PIONEERING

"Deuterium-Enabled
Chiral Switching"

to improve existing medicines

Recent News

Dr. Sheila DeWitt, President and CEO of DeuteRx, named one of the 20 “Women to Watch” in 2013 by Mass High Tech

"Start-Up Hurdles"” for women entrepreneurs in the chemical sciences features Dr. Sheila DeWitt

Success Story

DeuteRx, LLC is a spin-out company from Deuteria Pharmaceuticals, Inc. The success of Deuteria resulted from pioneering “Deuterium-Enabled Chiral Switching” (DECS). In December 2012, <2 years after incorporation, Deuteria was sold. Deuteria was funded entirely by loans from the founders. The former shareholders of Deuteria participated in the seed financing of DeuteRx.

Commercial Value

DeuteRx is revolutionizing the highly profitable model of ‘chiral switching’. Numerous drugs are still developed and sold as a mixture of two mirror-image compounds that interconvert. Representative drugs include Aricept®, Revlimid®, and Actos®. Introducing deuterium at the chiral center enables dosing of the single, preferred enantiomer to create an improved NCE with new composition of matter patent protection.